Chemists from Konstanz develop selective agents to combat infectious diseases – based on the structures of natural products
With multi-resistant germs becoming more and more of a threat, we are in need of new antibiotics now more than ever. Unfortunately, antibiotics cannot distinguish between pathogens and beneficial microbes. They can destroy the delicate balance of the microbiome – resulting in permanent damages. The research team around chemist Dr Thomas Böttcher has now made a significant step towards solving these problems. In collaboration with the team around biologist Professor Christof Hauck, also from Konstanz, the researchers discovered antibiotic properties of a natural product that so far had been considered merely a bacterial signal molecule. The team, including the doctoral researchers Dávid Szamosvári and Tamara Schuhmacher, developed and investigated synthetic derivatives of the natural substance that proved surprisingly efficient against the pathogen Moraxella catarrhalis. In the process only the growth of these pathogens was inhibited, not the growth of other bacteria. In a further project, the researchers succeed in developing another selective agent to combat the malaria parasite. These results might lead to a new basis for novel precision antibiotics. The research results are published in the current editions of the journals Chemical Science and Chemical Communications.
As important as antibiotics are to treat infectious diseases, they leave a trail of destruction in the human microbiome. Gastrointestinal disorders following antibiotic treatments are one of the slightest problems in this context. Quite often, resistant pathogens replace beneficial microbes. Later on, these can cause severe infectious diseases or chronic illnesses. However, not all microbes are dangerous. On the contrary, many microorganisms live in peaceful coexistence with us, and are even vital for human health. We humans are true microcosms and host more microbes than human cells. Yet this ecosystem, the human microbiome, is fragile. Allergies, overweight, chronic inflammatory bowel diseases and even psychiatric disorders may be the result of a damaged microbiome. The question is how can we maintain this ecological diversity in case of a microbial infection?
The research team originally studied the signals of the bacterium Pseudomonas aeruginosa. A compound aroused their interest as it was highly selectively inhibiting the growth of the pathogen Moraxella catarrhalis. This pathogen causes, for example, otitis media in children as well as infections in patients with chronically obstructive pulmonary diseases. The synthetic scaffold engineering of this natural product resulted in a new compound class with enormous antibiotic efficiency. What was really surprising was the substance’s selectivity: Only the growth of Moraxella catarrhalis was inhibited, not that of other bacteria. Even closely related bacteria from the same species remained completely unaffected.
Currently, Thomas Böttcher and Christof Hauck are investigating the mechanism of action of this highly selective antibiotic against the pathogen Moraxella catarrhalis. Antibiotics with such selectivity would make precision treatment possible and specifically eliminate pathogens while preserving the diversity of beneficial microbes.
Learn more: Selective antibiotics following nature’s example
The Latest on: Precision antibiotics
[google_news title=”” keyword=”precision antibiotics” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Precision antibiotics
- Precision medicine in PET imaging: AI-based attenuation correction for enhanced patient careon May 9, 2024 at 9:06 pm
A new research paper was published in Oncotarget's Volume 15 on May 7, 2024, entitled, "Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN." ...
- University of Hong Kong overhauls medicine programme to focus on innovation, fighting canceron May 9, 2024 at 4:40 pm
Dr Pamela Lee, faculty of medicine’s assistant dean, says restructured curriculum will take place October and affect year 4 students.
- Labroots Announces the 12th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2024on May 9, 2024 at 7:00 am
Labroots, the leading scientific social networking website and producer of educational virtual events and webinars, proudly announces the upcoming 12th Annual Precision Medicine Virtual Event Series.
- Imaging Endpoints Unveils Emboldened Path to Advance Precision Medicine with Revolution Endpoints™on May 7, 2024 at 9:52 pm
Imaging Endpoints IE, a global leader in Imaging CRO technologies and services, has announced the formation of a new subsidiary, Revolution Endpoints, focused on leveraging the Companys strong ...
- ECOG-ACRIN adds another trial to the ComboMATCH precision oncology study platformon May 7, 2024 at 5:00 pm
Another ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) treatment trial is open as part of the ComboMATCH precision medicine study platform. ComboMATCH-E5 is evaluating treatment for patients with KRAS ...
- IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Businesson May 7, 2024 at 5:30 am
On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between (NASDAQ: BACK) (“BACK”) and Theralink Technologies, Inc. (“Theralink”), BACK ...
- Precision medicine in Sjögren's diseaseon May 6, 2024 at 4:15 pm
Sjögren's disease is a clinically and pathophysiologically heterogeneous disease to which precision medicine, on the basis of clinical and biological heterogeneity, has been not always applicable. In ...
- Precision medicine tool predicts breast cancer immunotherapy responseon May 6, 2024 at 10:30 am
New InteractPrint tool analyzes how breast cancer epithelial cells impact cancer-immune interactions, enabling prediction of immune checkpoint inhibition response.
- Offshore wind, precision medicine among key areas for S’pore’s growth, says new EnterpriseSG chairmanon May 6, 2024 at 1:07 am
These are sectors that Singapore can maximise opportunities and contribute to its long-term growth. Read more at straitstimes.com.
- Can a personalized antibiotics, prebiotics, and probiotics combo help treat IBS?on May 4, 2024 at 11:00 pm
A pilot study suggests that a personalized combination of antibiotics, prebiotics, and probiotics may help treat the symptoms of post-infectious irritable bowel syndrome (IBS).
via Bing News